- Home
- AXS vs CORT Comparison
AXS vs CORT Comparison
Compare AXS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXS | CORT |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 8.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AXS | CORT |
|---|---|---|
| Price | $107.66 | $35.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $117.00 | ★ $130.20 |
| AVG Volume (30 Days) | 576.3K | ★ 2.1M |
| Earning Date | 01-28-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | ★ 68.27 | N/A |
| EPS | ★ 12.10 | 0.87 |
| Revenue | ★ $6,301,015,000.00 | $741,172,000.00 |
| Revenue This Year | $6.62 | $23.96 |
| Revenue Next Year | $8.61 | $43.40 |
| P/E Ratio | ★ $8.85 | $39.84 |
| Revenue Growth | 5.59 | ★ 17.92 |
| 52 Week Low | $83.90 | $32.99 |
| 52 Week High | $110.34 | $117.33 |
Technical Indicators
Market Signals| Indicator | AXS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 63.35 | 14.56 |
| Support Level | $105.67 | $80.38 |
| Resistance Level | $109.57 | $85.34 |
| Average True Range (ATR) | 1.51 | 4.01 |
| MACD | 0.03 | -3.98 |
| Stochastic Oscillator | 69.91 | 4.40 |
Price Performance
Historical ComparisonAbout AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States ("U.S."), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of AXIS Insurance and AXIS Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.